Impact of emerging hepatitis C virus treatments on future needs for liver transplantation in France: A modelling approach

Digestive and Liver Disease

Volumn 46, Issue 2, 2014, Pages 157-163

  Deuffic Burban, Sylvie ^a,b   Mathurin, Philippe ^a,c   Rosa, Isabelle ^d   Bouvier, Anne Marie ^e,f   Cannesson, Amélie ^c   Mourad, Abbas ^a,b   Canva, Valérie ^c   Louvet, Alexandre ^a,c   Deltenre, Pierre ^c,g   Boleslawski, Emmanuel ^c   Truant, Stéphanie ^c   Pruvot, François René ^c   Dharancy, Sébastien ^a,c  

^a UNIVERSITÉ DE LILLE   (France)

^b INSERM   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^e Institut Médical de Génétique et d Immunologie   (France)

^f DIJON UNIVERSITY HOSPITAL   (France)

^g Hospital de Jolimont   (Belgium)

Author keywords

Direct acting antiviral agents; HCV epidemic; Liver graft allocation; Markov model; Multi organ procurement

Indexed keywords

AGED; ALCOHOL CONSUMPTION; ARTICLE; DECOMPENSATED LIVER CIRRHOSIS; DISEASE COURSE; EPIDEMIC; FRANCE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER GRAFT; PRIORITY JOURNAL; SENSITIVITY ANALYSIS;

DIRECT-ACTING ANTIVIRAL AGENTS; HCV EPIDEMIC; LIVER GRAFT ALLOCATION; MARKOV MODEL; MULTI-ORGAN PROCUREMENT;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; FRANCE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MARKOV CHAINS; TISSUE AND ORGAN PROCUREMENT; TRANSPLANTS;

EID: 84893693698     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2013.08.137     Document Type: Article

References (54)

1. Lauer G.M., Walker B.D. Hepatitis C virus infection. The New England Journal of Medicine 2001, 345:41-52.
2. Adam R., Karam V., Delvart V., et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). Journal of Hepatology 2012, 57:675-688.
3. European Liver Transplant Registry. Overall indication and results. [Access date: March 26, 2013]. http://www.eltr.org/spip.php?article161.
4. Francoz C., Belghiti J., Castaing D., et al. Model for end-stage liver disease exceptions in the context of the French model for end-stage liver disease score-based liver allocation system. Liver Transplantation 2011, 17:1137-1151.
5. Dawwas M.F., Gimson A.E. Candidate selection and organ allocation in liver transplantation. Seminars in Liver Disease 2009, 29:40-52.
6. Deuffic-Burban S., Deltenre P., Buti M., et al. Predicted effects of treatment for HCV infection vary among European countries. Gastroenterology 2012, 143:974-985.
7. Deuffic-Burban S., Babany G., Lonjon-Domanec I., et al. Impact of pegylated interferon and ribavirin on morbidity and mortality in patients with chronic hepatitis C and normal aminotransferases in France. Hepatology 2009, 50:1351-1359.
8. Deuffic-Burban S., Deltenre P., Louvet A., et al. Impact of viral eradication on mortality related to hepatitis C: a modeling approach in France. Journal of Hepatology 2008, 49:175-183.
9. Poynard T., Bedossa P., Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997, 349:825-832.
10. Groupe d'experts Alcool - Dommages sociaux, abus et dépendances 2003, Expertise Collective - Les Editions INSERM, Paris.
11. Roudot-Thoraval F., Bastie A., Pawlotsky J.M., et al. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients, The Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus. Hepatology 1997, 26:485-490.
12. Martinot-Peignoux M., Roudot-Thoraval F., Mendel I., et al. Hepatitis C virus genotypes in France: relationship with epidemiology, pathogenicity and response to interferon therapy. The GEMHEP. Journal of Viral Hepatitis 1999, 6:435-443.
13. Payan C., Roudot-Thoraval F., Marcellin P., et al. Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study. Journal of Viral Hepatitis 2005, 12:405-413.
14. Pagliaro L., Peri V., Linea C., et al. Natural history of chronic hepatitis C. Italian Journal of Gastroenterology and Hepatology 1999, 31:28-44.
15. Poynard T., Ratziu V., Charlotte F., et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. Journal of Hepatology 2001, 34:730-739.
16. Serfaty L., Aumaitre H., Chazouilleres O., et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998, 27:1435-1440.
17. Corrao G., Arico S. Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. Hepatology 1998, 27:914-919.
18. Degos F., Christidis C., Ganne-Carrié N., et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 2000, 47:131-136.
19. D'Amico G., Garcia-Tsao G., Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. Journal of Hepatology 2006, 44:217-231.
20. Singal A.G., Volk M.L., Jensen D., et al. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clinical Gastroenterology and Hepatology 2010, 8(8):280-288. e1.
21. El-Serag H.B. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004, 127:S27-S34.
22. El-Serag H.B., Mason A.C., Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology 2001, 33:62-65.
23. Dubois F., Desenclos J.C., Mariotte N., et al. Hepatitis C in a French population-based survey 1994: seroprevalence, frequency of viremia, genotype distribution, and risk factors. Hepatology 1997, 25:1490-1496.
24. Meffre C., Le Strat Y., Delarocque-Astagneau E., et al. Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors. Journal of Medical Virology 2010, 82:546-555.
25. Pariente A., Lahmek P., Duprat C., et al. Treatment of chronic hepatitis C with pegylated interferon and ribavirin in treatment-naive patients in 'true life': a plea in favor of independent postmarketing evaluations. European Journal of Gastroenterology and Hepatology 2010, 22:1297-1302.
26. Bourliere M., Ouzan D., Rosenheim M., et al. Pegylated interferon-alpha2a plus ribavirin for chronic hepatitis C in a real-life setting: the Hepatys French cohort (2003-2007). Antiviral Therapy 2012, 17:101-110.
27. Shiffman M.L., Di Bisceglie A.M., Lindsay K.L., et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004, 126:1015-1023.
28. Poynard T., Colombo M., Bruix J., et al. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology 2009, 136:e2. 1618-28.
29. McHutchison J.G., Lawitz E.J., Shiffman M.L., et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. The New England Journal of Medicine 2009, 361:580-593.
30. Hezode C., Forestier N., Dusheiko G., et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. The New England Journal of Medicine 2009, 360:1839-1850.
31. Jacobson I.M., McHutchison J.G., Dusheiko G., et al. Telaprevir for previously untreated chronic hepatitis C virus infection. The New England Journal of Medicine 2011, 364:2405-2416.
32. Lawitz E., Mangia A., Wyles D., et al. Sofosbuvir for previously untreated chronic hepatitis C infection. The New England Journal of Medicine 2013, 368:1878-1887.
33. Gane E.J., Stedman C., Hyland R.H., et al. Once daily PSI-7977 plus RBV: pegylated interferon-alpha not required for complete rapid viral response in treatment-naive patients with HCV GT2 or GT3. Hepatology 2011, 54:377A.
34. Unpublished data of the Agence de la Biomédecine.
35. Consensus conference: indications for liver transplantation, January 19 and 20, 2005, Lyon-Palais Des Congres: text of recommendations (long version). Liver Transplantation 2006;12:998-1011.
36. Clavien P.A., Lesurtel M., Bossuyt P.M., et al. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncology 2012, 13:e11-e22.
37. Patel S.S., Arrington A.K., McKenzie S., et al. Milan criteria and UCSF criteria: a preliminary comparative study of liver transplantation outcomes in the United States. International Journal of Hepatology 2012, 2012:253517.
38. Guiu B., Minello A., Cottet V., et al. A 30-year, population-based study shows improved management and prognosis of hepatocellular carcinoma. Clinical Gastroenterology and Hepatology 2010, 8:986-991.
39. Rosa I., Denis J., Lesgourgues B., et al. A French multicentric longitudinal descriptive study of hepatocellular carcinoma management, the CHANGH cohort: preliminary results. Hepatology 2010, 52:1144A.
40. Castera L., Vergniol J., Foucher J., et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005, 128:343-350.
41. Borie F., Bouvier A.M., Herrero A., et al. Treatment and prognosis of hepatocellular carcinoma: a population based study in France. Journal of Surgical Oncology 2008, 98:505-509.
42. Decaens T., Roudot-Thoraval F., Hadni-Bresson S., et al. Impact of UCSF criteria according to pre- and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time. Liver Transplantation 2006, 12:1761-1769.
43. Carey W.D., Dumot J.A., Pimentel R.R., et al. The prevalence of coronary artery disease in liver transplant candidates over age 50. Transplantation 1995, 59:859-864.
44. Donovan C.L., Marcovitz P.A., Punch J.D., et al. Two-dimensional and dobutamine stress echocardiography in the preoperative assessment of patients with end-stage liver disease prior to orthotopic liver transplantation. Transplantation 1996, 61:1180-1188.
45. Tiukinhoy-Laing S.D., Rossi J.S., Bayram M., et al. Cardiac hemodynamic and coronary angiographic characteristics of patients being evaluated for liver transplantation. American Journal of Cardiology 2006, 98:178-181.
46. Pelletier S.J., Fu S., Thyagarajan V., et al. An intention-to-treat analysis of liver transplantation for hepatocellular carcinoma using organ procurement transplant network data. Liver Transplantation 2009, 15:859-868.
47. Lebrec D., Thabut D., Oberti F., et al. Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis. Gastroenterology 2010, 138:1755-1762.
48. CépiDc Inserm. Interrogation des données sur les causes de décès de 1979 à 2010. [Access date: July 22, 2013]. http://www.cepidc.inserm.fr/cgi/broker.exe.
49. Marcellin P., Pequignot F., Delarocque-Astagneau E., et al. Mortality related to chronic hepatitis B and chronic hepatitis C in France: Evidence for the role of HIV coinfection and alcohol consumption. Journal of Hepatology 2008, 48:200-207.
50. Roels L., Rahmel A. The European experience. Transplant International 2011, 24:350-367.
51. Lettmeier B., Muhlberger N., Schwarzer R., et al. Market uptake of new antiviral drugs for the treatment of hepatitis C. Journal of Hepatology 2008, 49:528-536.
52. Deuffic-Burban S., Mathurin P., Valleron A.J. Modelling the past, current and future HCV burden in France: detailed analysis and perspectives. Statistical Methods in Medical Research 2008.
53. Singal A.K., Guturu P., Hmoud B., et al. Evolving frequency and outcomes of liver transplantation based on etiology of liver disease. Transplantation 2013.
54. Agence de la Biomédecine. Cristal. [Access date: July 22, 2013]. http://www.agence-biomedecine.fr/Cristal.